Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
作者： C. Barrett , H. Magee , D. O'Toole , S. Daly , M. Jeffers
关键词:
摘要: Background: The majority of cases breast cancer scoring HER2 weak positive (2+) on immunohistochemistry (IHC) using the HercepTest are not associated with amplification HER2/neu gene. Aim: To examine reproducibility IHC in 2+ subsequently shown to have gene by fluorescence in-situ hybridisation (FISH). Methods: A retrospective analysis 153 referred for FISH confirmation a result was performed. Repeat undertaken referral and FISH. Results: Amplification confirmed 29/153 (19%) IHC. carried out 25 cases: 7 (28%) scored repeat IHC, 18 (72%) 3+ were reclassified as strong positive. heterogeneous expression pattern present 3/17 3+. Conclusions: results accompanied represent “false positive” terms prognostic or therapeutic relevance. small proportion scores true amplification: category probably biologically related cases. remainder HercepTest™ positive, amplified, best described negative IHC”. This has implications selection where score is used triage testing, testing strategies laboratories undertaking analysis.
sci-hub.se 参考文章(29)
Godolphin W, Pauletti G, Press Mf, Slamon Dj, Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. ,vol. 13, pp. 63- 72 ,(1996)
Lauren Hammock, Melinda Lewis, Carol Phillips, Cynthia Cohen, Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization1 1This manuscript consists of original material not previously accepted for publication by another journal. The manuscript does not include use of any investigational or “off-label” products. The authors do not have a financial or other relationship with any of the commercial enterprises whose products or services may be discussed in this original article. Human Pathology. ,vol. 34, pp. 1043- 1047 ,(2003) , 10.1053/S0046-8177(03)00409-X
Michael F. Press, Dennis J. Slamon, Kerry J. Flom, Jinha Park, Jian-Yuan Zhou, Leslie Bernstein, Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens Journal of Clinical Oncology. ,vol. 20, pp. 3095- 3105 ,(2002) , 10.1200/JCO.2002.09.094
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
A Jukkola, R Bloigu, Y Soini, E.-R Savolainen, K Holli, G Blanco, c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. European Journal of Cancer. ,vol. 37, pp. 347- 354 ,(2001) , 10.1016/S0959-8049(00)00395-6
O. P. Kallioniemi, A. Kallioniemi, W. Kurisu, A. Thor, L. C. Chen, H. S. Smith, F. M. Waldman, D. Pinkel, J. W. Gray, ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 5321- 5325 ,(1992) , 10.1073/PNAS.89.12.5321
Hadi Yaziji, HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods JAMA. ,vol. 291, pp. 1972- 1977 ,(2004) , 10.1001/JAMA.291.16.1972
Elizabeth L. Wiley, Leslie K. Diaz, High-Quality HER-2 Testing JAMA. ,vol. 291, pp. 2019- 2020 ,(2004) , 10.1001/JAMA.291.16.2019
J.M.S. Bartlett, E. Mallon, T. Cooke, Molecular diagnostics for determination of HER2 status in breast cancer Current Diagnostic Pathology. ,vol. 9, pp. 48- 55 ,(2003) , 10.1054/CDIP.2002.0155
M Dowsett, J Bartlett, IO Ellis, J Salter, M Hills, E Mallon, AD Watters, T Cooke, C Paish, PM Wencyk, SE Pinder, Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. The Journal of Pathology. ,vol. 199, pp. 418- 423 ,(2003) , 10.1002/PATH.1313